Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 2/2013

01-02-2013 | CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Racial and Gender Disparities Among Patients with Gout

Author: Jasvinder A. Singh

Published in: Current Rheumatology Reports | Issue 2/2013

Login to get access

Abstract

Gout affects 8.3 million Americans according to NHANES 2007–2008, approximately 3.9 % of the US population. Gout has substantial effect on physical function, productivity, health-related quality of life (HRQOL), and health care costs. Uncontrolled gout is also associated with significant use of emergency care services. Women are less likely to have gout than men, but in the postmenopausal years the gender difference in disease incidence decreases. Compared with whites, racial and/or ethnic minorities, especially blacks, have higher prevalence of gout. Blacks are also less likely to receive quality gout care, leading to disproportionate morbidity. Women are less likely than men to receive allopurinol, and less likely to undergo joint aspirations for crystal analysis to establish diagnosis, but those on urate-lowering therapy are as likely as, or more likely than, men to undergo serum urate check within six months of initiation. Although a few studies provide the knowledge related to gender and race and/or ethnicity disparities for gout, several knowledge gaps exist in gout epidemiology and outcomes differences by gender and race and/or ethnicity. These should be investigated in future studies.
Literature
1.
Kimball MM, Neal D, Waters MF, Hoh BL. Race and income disparity in ischemic stroke care: nationwide inpatient sample database, 2002 to 2008. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. Jul 17 2012
2.
Wellons MF, Fujimoto VY, Baker VL, et al. Race matters: a systematic review of racial and/or ethnic disparity in Society for Assisted Reproductive Technology reported outcomes. Fertil Steril. 2012;98(2):406–9.PubMedCrossRef
3.
Sclar DA, Robison LM, Schmidt JM, Bowen KA, Castillo LV, Oganov AM. Diagnosis of depression and use of antidepressant pharmacotherapy among adults in the United States: does a disparity persist by ethnicity/race? Clin Drug Investig. 2012;32(2):139–44.PubMedCrossRef
4.
Kreatsoulas C, Anand SS. Disparity in outcomes of surgical revascularization for limb salvage. Race and gender are synergistic determinants of vein graft failure and limb loss. Nguyen LL, Hevelone N, Rogers SO, Bandyk DF, Clowes AW, Moneta GL, Lipsitz S, Conte MS. Circulation. 2009; 119: 123–130. Vasc Med. Nov 2009;14(4):397–399
5.
Lam BL, Lee DJ, Zheng DD, Davila EP, Christ SL, Arheart KL. Disparity in prevalence of self-reported visual impairment in older adults among U.S. race-ethnic subgroups. Ophthalmic Epidemiol. 2009;16(3):144–50.PubMedCrossRef
6.
Tomson CR, Foley RN, Li Q, Gilbertson DT, Xue JL, Collins AJ. Race and end-stage renal disease in the United States Medicare population: the disparity persists. Nephrology (Carlton). 2008;13(7):651–6.CrossRef
7.
Hlaing WM. Race/ethnic disparity in hypertension-related hospitalization in Florida. Ethn Dis. 2007;17(3):453–60.PubMed
8.
Chang KJ, Parasher G, Christie C, Largent J, Anton-Culver H. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer 2005;103(2):349–57.
9.
Hawker GA. The quest for explanations for race/ethnic disparity in rates of use of total joint arthroplasty. J Rheumatol. 2004;31(9):1683–5.PubMed
10.
Wenger NS, Pearson ML, Desmond KA, et al. Epidemiology of do-not-resuscitate orders. Disparity by age, diagnosis, gender, race, and functional impairment. Arch Intern Med. 1995;155(19):2056–62.PubMedCrossRef
11.
Cox ED, Nackers KA, Young HN, Moreno MA, Levy JF, Mangione-Smith RM. Influence of race and socioeconomic status on engagement in pediatric primary care. Patient Educ Couns. 2012;87(3):319–26.PubMedCrossRef
12.
Yao L, Robert SA. Examining the racial crossover in mortality between African American and White Older adults: a multilevel survival analysis of race, individual socioeconomic status, and neighborhood socioeconomic context. J Aging Res. 2011;2011:132073.PubMed
13.
Chu DI, Moreira DM, Gerber L, et al. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. Mar 13 2012
14.
Trinh QD, Sun M, Sammon J, et al. Disparities in access to care at high-volume institutions for uro-oncologic procedures. Cancer. Feb 1 2012
15.
FitzGerald JD, Soohoo NF, Losina E, Katz JN. Potential impact on patient residence to hospital travel distance and access to care under a policy of preferential referral to high-volume knee replacement hospitals. Arthritis Care Res. 2012;64(6):890–7.CrossRef
16.
Langford AT, Resnicow K, Roberts JS, Zikmund-Fisher BJ. Racial and ethnic differences in direct-to-consumer genetic tests awareness in HINTS 2007: sociodemographic and numeracy correlates. J Genet Couns. 2012;21(3):440–7.PubMedCrossRef
17.
Cene CW, Roter D, Carson KA, Miller 3rd ER, Cooper LA. The effect of patient race and blood pressure control on patient–physician communication. J Gen Intern Med. 2009;24(9):1057–64.PubMedCrossRef
18.
Gordon HS, Street Jr RL, Kelly PA, Souchek J, Wray NP. Physician–patient communication following invasive procedures: an analysis of post-angiogram consultations. Soc Sci Med. 2005;61(5):1015–25.PubMedCrossRef
19.
Johnson RL, Roter D, Powe NR, Cooper LA. Patient race and/or ethnicity and quality of patient–physician communication during medical visits. Am J Public Health. 2004;94(12):2084–90.PubMedCrossRef
20.
Manfredi C, Kaiser K, Matthews AK, Johnson TP. Are racial differences in patient–physician cancer communication and information explained by background, predisposing, and enabling factors? J Heal Commun. 2010;15(3):272–92.CrossRef
21.
Jeon-Slaughter H. Economic factors in of patients’ nonadherence to antidepressant treatment. Soc Psychiatry Psychiatr Epidemiol. Mar 14 2012
22.
Byrne MM, Souchek J, Richardson M, Suarez-Almazor M. Racial and/or ethnic differences in preferences for total knee replacement surgery. J Clin Epidemiol. 2006;59(10):1078–86.PubMedCrossRef
23.
Rosen AB, Tsai JS, Downs SM. Variations in risk attitude across race, gender, and education. Med Dec Making Int J Soc Med Dec Making. 2003;23(6):511–7.CrossRef
24.
Ibrahim SA, Siminoff LA, Burant CJ, Kwoh CK. Differences in expectations of outcome mediate African American/white patient differences in “willingness” to consider joint replacement. Arthritis Rheum. 2002;46(9):2429–35.PubMedCrossRef
25.
Hofmann JC, Wenger NS, Davis RB, et al. Patient preferences for communication with physicians about end-of-life decisions. SUPPORT Investigators. Study to understand prognoses and preference for outcomes and risks of treatment. Ann Intern Med. 1997;127(1):1–12.PubMed
26.
Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med. 1993;329(9):621–7.PubMedCrossRef
27.
Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47(3):350–5.PubMedCrossRef
28.
Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care (full printed version). Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. ISBN: 0-309-50911-4, 782 pages, 6 × 9, (2003). http://​www.​nap.​edu/​catalog/​10260.​html. 2003
29.
Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. J Natl Med Assoc. 2002;94(8):666–8.PubMed
30.
Nelson AR. Unequal treatment: report of the Institute of Medicine on racial and ethnic disparities in healthcare. Ann Thorac Surg. 2003;76(4):S1377–1381.PubMedCrossRef
31.
32.
Cartwright-Smith L, Rosenbaum S, Mehta D. Disparities Reduction and Minority Health Improvement under the ACA. Vol 3. Washington, D.C.: The George Washington University School of Public Health and Health Services; 2011:1–6
33.
34.
Birnie D, Tung S, Simpson C, et al. Complications associated with defibrillation threshold testing: the Canadian experience. Heart Rhythm Off J Heart Rhythm Soc. 2008;5(3):387–90.CrossRef
35.
Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA. 2007;298(13):1517–24.PubMedCrossRef
36.
Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298(13):1525–32.PubMedCrossRef
37.
Kaul P, Chang WC, Westerhout CM, Graham MM, Armstrong PW. Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes. CMAJ. 2007;177(10):1193–9.PubMedCrossRef
38.
Bierman AS, Pugh MJ, Dhalla I, et al. Sex differences in inappropriate prescribing among elderly veterans. Am J Geriatr Pharmacother. 2007;5(2):147–61.PubMedCrossRef
39.
40.
41.
•• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41. This is the first comprehensive population-based epidemiological study of the prevalence of gout in the US general population.PubMedCrossRef
42.
Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum Jan. 2008;58(1):15–25.CrossRef
43.
Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67(9):1310–6.PubMedCrossRef
44.
Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10–5.PubMedCrossRef
45.
Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health. 2007;10(4):231–7.PubMedCrossRef
46.
Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case–control study. Rheumatology (Oxford). 2007;46(9):1441–4.CrossRef
47.
Khanna D, Ahmed M, Yontz D, et al. The disutility of chronic gout. Qual Life Res. 2008;17(5):815–22.PubMedCrossRef
48.
Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688–96.PubMedCrossRef
49.
•• De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69(6):1162–4. This is a high-quality cohort study assessing gout as a risk factor for cardiac outcomes.PubMedCrossRef
50.
Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, Group MR. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104–10.PubMedCrossRef
51.
•• Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2(1):e000282. This high-quality cohort study established a link between gout and heart failure.PubMedCrossRef
52.
Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008;19(11):2204–10.PubMedCrossRef
53.
• Charles BA, Shriner D, Doumatey A, et al. A genome-wide association study of serum uric acid in African Americans. BMC Med Genomics. 2011;4:17. This study highlights the genetic correlates of serum uric acid in minorities.PubMedCrossRef
54.
Rule AD, de Andrade M, Matsumoto M, Mosley TH, Kardia S, Turner ST. Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families. Rheumatology (Oxford). 2011;50(5):871–8.CrossRef
55.
Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38(5):628–32.PubMedCrossRef
56.
Maynard JW, McAdams Demarco MA, Baer AN, et al. Incident Gout in Women and Association with Obesity in the Atherosclerosis Risk in Communities (ARIC) study. Am J Med. 2012;125(7):717 e719–7.CrossRef
57.
Portis AJ, Laliberte M, Tatman P, et al. High prevalence of gouty arthritis among the Hmong population in Minnesota. Arthritis Care Res (Hoboken). 2010;62(10):1386–91.CrossRef
58.
Wahedduddin S, Singh JA, Culhane-Pera KA, Gertner E. Gout in the Hmong in the United States. J Clin Rheumatol. 2010;16(6):262–6.PubMedCrossRef
59.
60.
Stanhope JM, Prior IA. Uric acid, joint morbidity, and streptococcal antibodies in Maori and European teenagers. Rotorua Lakes study 3. Ann Rheum Dis. 1975;34(4):359–63.PubMedCrossRef
61.
•• Juraschek SP, Miller 3rd ER, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988–1994 and 2007–2010: body mass index, obesity, and gout. Arthritis Care Res (Hoboken). 2012. This study used NHANES data and described the association between obesity and prevalent gout over time.
62.
Phipps-Green AJ, Hollis-Moffatt JE, Dalbeth N, et al. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets. Hum Mol Genet. 2010;19(24):4813–9.PubMedCrossRef
63.
Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med Jan. 1967;42(1):27–37.CrossRef
64.
Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29(11):2403–6.PubMed
65.
Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis. 1979;38(2):101–6.PubMedCrossRef
66.
Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995;48(9):1153–8.PubMedCrossRef
67.
Grodzicki T, Palmer A, Bulpitt CJ. Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. The General Practice Hypertension Study Group. J Hum Hypertens Sep. 1997;11(9):583–5.CrossRef
68.
De Souza AW, Fernandes V, Ferrari AJ. Female gout: clinical and laboratory features. J Rheumatol. 2005;32(11):2186–8.PubMed
69.
Akizuki S. A population study of hyperuricaemia and gout in Japan—analysis of sex, age and occupational differences in thirty-four thousand people living in Nagano Prefecture. Ryumachi [Rheumatism]. 1982;22(3):201–8.
70.
Chen JH, Yeh WT, Chuang SY, Wu YY, Pan WH. Gender-specific risk factors for incident gout: a prospective cohort study. Clin Rheumatol. 2012;31(2):239–45.PubMedCrossRef
71.
Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet Jun. 2009;5(6):e1000504.CrossRef
72.
Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303–7.PubMedCrossRef
73.
Wells AF, MacDonald PA, Chefo S, Jackson RL. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord. 2012;13:15.PubMedCrossRef
74.
Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008;48(9):1014–24.PubMedCrossRef
75.
Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822–9.PubMedCrossRef
76.
Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35(3):498–501.PubMed
77.
Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67(5):609–13.PubMedCrossRef
78.
Harrold LR, Yood RA, Mikuls TR, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1368–72.PubMedCrossRef
79.
Singh JA. Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial. BMC Med. 2012;10:15.PubMedCrossRef
Metadata
Title
Racial and Gender Disparities Among Patients with Gout
Author
Jasvinder A. Singh
Publication date
01-02-2013
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 2/2013
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-012-0307-x

Other articles of this Issue 2/2013

Current Rheumatology Reports 2/2013 Go to the issue

SCLERODERMA (J VARGA, SECTION EDITOR)

Involvement of PDGF in Fibrosis and Scleroderma: Recent Insights from Animal Models and Potential Therapeutic Opportunities

CHRONIC PAIN (LJ CROFFORD, SECTION EDITOR)

Nonpharmacological Treatment of Pain in Rheumatic Diseases and Other Musculoskeletal Pain Conditions

SCLERODERMA (J VARGA, SECTION EDITOR)

Recent Developments in Diagnosis and Assessment of Morphea

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Genetics of Hyperuricemia and Gout: Implications for the Present and Future

CHRONIC PAIN (LJ CROFFORD, SECTION EDITOR)

Low Back Pain and Lumbar Spine Osteoarthritis: How Are They Related?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits